Next Article in Journal
Research in Perioperative Care of the Cancer Patient: Opportunities and Challenges
Previous Article in Journal
Diagnostic Value of Diffusion-Weighted Imaging with Background Body Signal Suppression (DWIBS) for the Pre-Therapeutic Loco-Regional Staging of Cervical Cancer: A Feasibility and Interobserver Reliability Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 30
Issue 1
10.3390/curroncol30010090
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

by
Manon Lefebvre
1,*,
Mathilde Duchatelet
1,
Houssein El Hajj
1,
Antoine De Courrèges
2,
Jennifer Wallet
2,
Charlotte Bellier
3,
Florence Le Tinier
4,
Marie Cécile Le Deley
2,
Carlos Martinez Gomez
1,5,
Eric Leblanc
1,5,
Fabrice Narducci
1,5 and
Delphine Hudry
1,5
1
Department of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, France
2
Methodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, France
3
Department of Medical Oncology, Centre Oscar Lambret, 59000 Lille, France
4
Academic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, France
5
Univ. Lille, Inserm, CHU Lille, U1192—Protéomique Réponse Inflammatoire Spectrométrie de Masse—PRISM, 59000 Lille, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2023, 30(1), 1174-1185; https://doi.org/10.3390/curroncol30010090
Submission received: 12 December 2022 / Revised: 2 January 2023 / Accepted: 12 January 2023 / Published: 14 January 2023
Browse Figures
Review Reports Versions Notes

Abstract

This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (p = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (p = 0.056). In contrast, OS (p = 0.97) and PFS (p = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors.
Keywords: clear cell uterine carcinoma; serous uterine carcinoma; stage I; survival; toxicities clear cell uterine carcinoma; serous uterine carcinoma; stage I; survival; toxicities

Share and Cite

MDPI and ACS Style

Lefebvre, M.; Duchatelet, M.; El Hajj, H.; De Courrèges, A.; Wallet, J.; Bellier, C.; Le Tinier, F.; Le Deley, M.C.; Martinez Gomez, C.; Leblanc, E.; et al. Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? Curr. Oncol. 2023, 30, 1174-1185. https://doi.org/10.3390/curroncol30010090

AMA Style

Lefebvre M, Duchatelet M, El Hajj H, De Courrèges A, Wallet J, Bellier C, Le Tinier F, Le Deley MC, Martinez Gomez C, Leblanc E, et al. Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? Current Oncology. 2023; 30(1):1174-1185. https://doi.org/10.3390/curroncol30010090

Chicago/Turabian Style

Lefebvre, Manon, Mathilde Duchatelet, Houssein El Hajj, Antoine De Courrèges, Jennifer Wallet, Charlotte Bellier, Florence Le Tinier, Marie Cécile Le Deley, Carlos Martinez Gomez, Eric Leblanc, and et al. 2023. "Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?" Current Oncology 30, no. 1: 1174-1185. https://doi.org/10.3390/curroncol30010090

APA Style

Lefebvre, M., Duchatelet, M., El Hajj, H., De Courrèges, A., Wallet, J., Bellier, C., Le Tinier, F., Le Deley, M. C., Martinez Gomez, C., Leblanc, E., Narducci, F., & Hudry, D. (2023). Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? Current Oncology, 30(1), 1174-1185. https://doi.org/10.3390/curroncol30010090

Article Metrics

Back to TopTop